Posts by Sammy Elmariah, MD, MPH
-
Aortic Valve Replacement Substantially Underutilized for Severe Aortic Stenosis
Shawn X. Li, MD, MBA, Sammy Elmariah, MD, MPH, and colleagues warn that the marked and rapid growth in the annual volume of aortic valve replacements being performed has been paralleled by equally rapid growth in the number of patients with severe aortic stenosis and an indication for the procedure.
-
Studies Investigate Transfemoral Mitral Valve Replacement
Massachusetts General Hospital is among the first in the U.S. to perform two different novel transfemoral mitral valve replacement procedures to treat mitral regurgitation.
-
Cerebral Embolic Protection Device May Not Reduce Stroke Risk After Transcatheter Aortic Valve Implantation
Dhaval Kolte, MD, PhD, and Sammy Elmariah, MD, MPH, and colleagues determined from a nationally representative database that using a cerebral embolic protective device during transcatheter aortic valve implantation was not associated with lower rates of in-hospital stroke, transient ischemic attack or mortality.
-
Review: Managing Severe Aortic Stenosis in the COVID-19 Era
In the absence of medical society guidelines, Massachusetts General Hospital cardiologists recommend best practices for managing patients with severe aortic stenosis under the resource constraints imposed by COVID-19.
-
Tricuspid Valve Repair and Tricuspid Valve Replacement Successfully Performed at Mass General
A tricuspid valve replacement and tricuspid valve repair–both involving catheter-based systems designed specifically for patients with tricuspid valve disease–have been successfully performed at Mass General.
-
Hospital PCI Volume Unrelated to Outcomes of Transcatheter Valve Replacement, Repair
The first study to examine whether hospital volume of percutaneous coronary interventions is associated with the outcomes of structural heart procedures found no association between the two metrics.
-
POPular TAVI Reveals No Need for Clopidogrel in Afib Patients Undergoing TAVR
The POPular TAVI trial shows that atrial fibrillation patients undergoing TAVR have lower mortality rates and bleed less when administered oral anticoagulation (OAC) alone than in combination with clopidogrel, supporting the current standard of not administering clopidogrel.
-
Pulmonary Hypertension Increases Risk of Poor Outcomes After Transcatheter Mitral Valve Repair
Pulmonary hypertension was common in patients with severe mitral valve regurgitation and was associated with increased mortality and readmissions for heart failure after transcatheter mitral valve repair.
-
Optimizing Clinical Outcomes for Patients with Valvular Stenosis
Sammy Elmariah, MD, MPH, discusses his interest in helping patients with valvular heart disease, specifically severe aortic stenosis, get treatment early.
-
TAVR Provides Benefits Over SAVR in Patients with Prior CABG
A comparative analysis of outcomes for patients undergoing aortic valve replacement show statistically significant benefits of transcatheter versus surgical modes.
Biography
Dr. Elmariah graduated from the University of Pennsylvania School of Medicine and completed his internal medicine residency training at the Hospital of the University of Pennsylvania. He subsequently served as Chief Medical Resident at Lankenau Hospital. Dr. Elmariah completed his fellowship in cardiovascular medicine at the Mount Sinai Hospital in New York where he also served as Chief Fellow. While a fellow, he also completed a Masters in Public Health at the Harvard School of Public Health. Dr. Elmariah completed further fellowship training in interventional cardiology and structural heart disease at the Massachusetts General Hospital.
Currently, Dr. Elmariah is an interventional cardiologist and structural heart disease specialist at the Massachusetts General Hospital and Assistant Professor of Medicine at the Harvard Medical School. In addition, he serves as the Director of Interventional Structural Heart Disease at the Boston VA Healthcare System. He is also the Associate Director of Trial Design at the Harvard Clinical Research Institute.
His clinical interest is in the management of valvular heart disease, coronary artery disease, and adult congenital heart disease. He performs transcatheter valve replacement, percutaneous coronary interventions (stents), and transcatheter closure of patent foramen ovale (PFO) and atrial septal defects (ASD).
Dr. Elmariah has a specific research interest in valvular heart disease. In addition to ongoing clinical investigation of valve calcification and the progression of aortic stenosis, Dr. Elmariah is evaluating the impact of transcatheter aortic valve replacement on myocardial metabolism and myocardial remodeling. Dr. Elmariah is an MGH Heart Center Hassenfeld Research Scholar and has been awarded the Jeremiah Stamler Distinguished Young Investigator Award and an American College of Cardiology Young Investigator Award.